Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.
Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check19 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedSeveral key URLs related to genetics, melanoma, and clinical trials have been removed, which may impact access to important medical information and resources.SummaryDifference4%
- Check48 days agoChange DetectedThe website has been updated to version 2.12.2, with new additions including links to genetics resources, clinical trial documents, and drug information for melanoma treatments such as Trametinib, Dabrafenib, and Pembrolizumab.SummaryDifference4%
- Check56 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
- Check63 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential improvements or features.SummaryDifference0.1%
Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.